[
  {
    "ts": null,
    "headline": "Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer",
    "summary": "NEW YORK, April 26, 2025--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a clini",
    "url": "https://finnhub.io/api/news?id=c6e392f9c4b9cf88c0f7fe5af1cfb0dd5f94b5b090ad3ce0e0b0a80352626ee6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745688600,
      "headline": "Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer",
      "id": 134104621,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, April 26, 2025--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a clini",
      "url": "https://finnhub.io/api/news?id=c6e392f9c4b9cf88c0f7fe5af1cfb0dd5f94b5b090ad3ce0e0b0a80352626ee6"
    }
  },
  {
    "ts": null,
    "headline": "Microsoft, Apple Set To Report Earnings As Markets Watch Out For Core PCE Price Index",
    "summary": "Tech giants MSFT, AAPL, META & AMZN are set to report earnings this week. Investors also look out for major economic indicators due on Friday. See an update here.",
    "url": "https://finnhub.io/api/news?id=d78c26e18c68b7705191062a2c17e2e55a608a8277fc05a553bb1186f0311979",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745665200,
      "headline": "Microsoft, Apple Set To Report Earnings As Markets Watch Out For Core PCE Price Index",
      "id": 134100310,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Tech giants MSFT, AAPL, META & AMZN are set to report earnings this week. Investors also look out for major economic indicators due on Friday. See an update here.",
      "url": "https://finnhub.io/api/news?id=d78c26e18c68b7705191062a2c17e2e55a608a8277fc05a553bb1186f0311979"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics: New Ivonescimab Data Raise Concerns",
    "summary": "Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT is a Hold or a Sell.",
    "url": "https://finnhub.io/api/news?id=92bceb505c1aee24c404474d888a9c2323eadb0e7d1a36fd0ffa7b1d3a24be3b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745659800,
      "headline": "Summit Therapeutics: New Ivonescimab Data Raise Concerns",
      "id": 134099846,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2181270761/image_2181270761.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT is a Hold or a Sell.",
      "url": "https://finnhub.io/api/news?id=92bceb505c1aee24c404474d888a9c2323eadb0e7d1a36fd0ffa7b1d3a24be3b"
    }
  }
]